cariporide has been researched along with erlotinib hydrochloride in 1 studies
| Studies (cariporide) | Trials (cariporide) | Recent Studies (post-2010) (cariporide) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 409 | 10 | 79 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | cariporide (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, F; Bellizzi, A; Bruns, P; Cardone, RA; Casavola, V; Greco, MR; Kalthoff, H; Menga, M; Pilarsky, C; Reshkin, SJ; Saccomano, M; Schwab, A; Zaccagnino, A; Zeeberg, K | 1 |
1 other study(ies) available for cariporide and erlotinib hydrochloride
| Article | Year |
|---|---|
A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.
Topics: Animals; Anti-Arrhythmia Agents; Blotting, Western; Carcinoma, Pancreatic Ductal; Cation Transport Proteins; Cell Line; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Guanidines; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sulfones | 2015 |